

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab and a taxane [ID3909]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation), and, if so, what are they?

No potential equality issues have been identified during the scoping process.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Not applicable.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Henry Edwards

Date: 03/02/22